At a glance
ClinicalIndex Comparison RecordN/ACompleted· 75 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Peripheral Gene Expression of Endocannabinoid System Components in Episodic and Chronic Migraine Patients: a Pilot Study
IRCCS National Neurological Institute "C. Mondino" Foundation·observational·Posted Mar 27, 2020·Updated Mar 27, 2020
In Brief
An observational study for Chronic Migraine. Completed, enrolled 75 participants across 1 site.
Detailed Summary
Preclinical and clinical evidence suggests a role for the dysregulation of endocannabinoid system (ES) in migraine pain, particularly in subjects with chronic migraine. The gene expression of ES components were assayed in peripheral blood mononuclear cells (PBMCs) of patients with episodic migraine (EM), chronic migraine with medication overuse (CM-MO) and age-matched healthy controls (CT). It was evaluated the protein expression of cannabinoid receptors (CB) 1 and 2 as well as DNA methylation changes in genes involved in ES components.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Migraine
CountriesItaly
CollaboratorsMinistry of Health, Italy
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartDec 2017
Primary CompletionDec 2019
First PostedMar 2020
TodayJul 2026
First PostedMar 27, 2020
Enrollment StartDec 12, 2017
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.3 years ago